Home/Pipeline/Celiprolol

Celiprolol

Vascular Ehlers-Danlos Syndrome (VEDS) - COL3A1 positive

Phase 3Ongoing (DiSCOVER trial enrolling)

Key Facts

Indication
Vascular Ehlers-Danlos Syndrome (VEDS) - COL3A1 positive
Phase
Phase 3
Status
Ongoing (DiSCOVER trial enrolling)
Company

About Zevra Therapeutics

Zevra Therapeutics is a purpose-driven rare disease company with a dual focus on commercial execution and late-stage clinical development. Its strategy involves following scientific data to build compelling regulatory narratives that address significant unmet patient needs. With a seasoned leadership team and a pipeline anchored in rare neurological and genetic disorders, Zevra aims to become a leader in the orphan drug space by advancing transformative therapies.

View full company profile